Nanjing XiZe Biotechnology

Nanjing XiZe Biotechnology is a clinical-stage biopharmaceutical company based in Nanjing, China, specializing in the discovery and development of innovative small molecule targeted therapies for oncology. The company's lead candidate, XZP-3621, is a potent ALK/ROS1 inhibitor currently in Phase 3 clinical trials for the treatment of non-small cell lung cancer. XiZe's pipeline also features several early-stage programs targeting the Hippo signaling pathway through TEAD inhibition and the DNA damage response via USP1 inhibition. By focusing on precision medicine and high-potential biological targets, the company aims to address significant unmet needs in the global cancer treatment landscape.